🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Breast Cancer
Clinical trial register · China

Advanced Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 16 Beijing 13 Guangzhou 6 Harbin 5 Fuzhou 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University4 Wenjin Yin4 Henan Cancer Hospital3 Xuanzhu Biopharmaceutical Co., Ltd.2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2
Site location
Shanghai16 Beijing13 Guangzhou6 Harbin5 Fuzhou4
All 25 locations
Target enrolment
to

Advanced Breast Cancer trials in China

46 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
NCT07766772HER2 + Breast Cancer, Advanced Breast Cancer
DrugsPyrotinib·Trastuzumab Rezetecan·Trastuzumab·Capecitabine
Fujian Cancer Hospital
Phase 2
50
Fuzhou
2026-09-30
Recruiting
Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
NCT07602907Advanced Breast Cancer, HER2-negative Breast Cancer
DrugPaclitaxel
Zhejiang Cancer Hospital
Phase 2
73
Hangzhou
2026-08-04
Not yet open
Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
NCT07684456Advanced Breast Cancer
DrugsUtidelone·Capecitabine
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 3
308
Beijing
2026-08-01
Recruiting
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
NCT07591090Advanced Breast Cancer
DrugsAK146D1·Bevacizumab
Akeso
Phase 2
200
Shanghai
2026-07-17
Recruiting
Timing of ctDNA Testing in Advanced Breast Cancer
NCT07681323Advanced Breast Cancer
Geneplus-Beijing Co. Ltd.
Observational
400
Beijing
2026-07-08
Recruiting
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
NCT07600164HER2 + Breast Cancer, Advanced Breast Cancer
DrugsPyrotinib·Trastuzumab Rezetecan
Peking University People's Hospital
Phase 4
500
Beijing
2026-07-06
Not yet open
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
NCT07560475HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer
DrugTrastuzumab Rezetecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-10
Not yet open
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
NCT07630103Advanced Breast Cancer
DrugsTrastuzumab Rezetecan·Trastuzumab deruxtecan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
100
Guangzhou
2026-06
Recruiting
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
NCT07597629Advanced Breast Cancer
DrugsSYS6023·KN026
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
36
Harbin
2026-05-25
Recruiting
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
NCT07540533Advanced Breast Cancer
DrugTislelizumab
Henan Cancer Hospital
Phase 2
92
Zhengzhou
2026-01-20
Recruiting
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
NCT07130383Advanced Breast Cancer, Advanced Malignant Solid Tumor
DrugsMHB036C·MHB039A
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2
210
Shanghai
2025-09-30
Not yet open
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
NCT07125950Advanced Breast Cancer
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2025-09-30
Recruiting
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
NCT07180160Advanced Breast Cancer
DrugsIparomlimab and Tuvonralimab·Fulvestrant
Wenjin Yin
Phase 2
123
Shanghai
2025-09-25
Recruiting
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
NCT07180082Advanced Breast Cancer
DrugPyrotinib
Wenjin Yin
Phase 2
186
Shanghai
2025-08-28
Recruiting
Trastuzumab Deruxtecan in Advanced Breast Cancer
NCT07180264Advanced Breast Cancer
DrugTrastuzumab deruxtecan
Wenjin Yin
Observational
118
Shanghai
2025-08-28
Recruiting
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
NCT07037199Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
45
Guangzhou
2025-08-18
Not yet open
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
NCT07041437Advanced Breast Cancer
DrugsSHR-A2102·Adebrelimab
Fudan University
Phase 2
48
Shanghai
2025-06-30
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Recruiting
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
NCT06769425Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
157
Shanghai
2025-05-07
Not yet open
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
NCT06750848Advanced Breast Cancer
Jundong Wu
Phase 2
48
Shantou
2024-12-20
Recruiting
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer
DrugsSHR-A1921·SHR-A2009·Famitinib·9MW2821
Fudan University
Phase 2
160
Shanghai
2024-10-21
Recruiting
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
NCT06102824HER2-negative Breast Cancer, Advanced Breast Cancer
DrugsXeloda·Liposomal doxorubicin·Paraplatin·Abraxane
Guangdong Provincial People's Hospital
Phase 2
252
Guangzhou
2024-10-01
Recruiting
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
NCT06776861Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
150
Beijing
2024-09-24
Active, closed
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment
NCT06500494Advanced Breast Cancer
Pierre Fabre Medicament
Observational
368
Tianjin
2024-09-10
Recruiting
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
NCT06656624Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
190
Nanjing
2024-08-13
Recruiting
Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
NCT06548919ESR1 Gene Mutation, Advanced Breast Cancer
SciClone Pharmaceuticals
Observational
450
Suzhou
2024-08-08
Recruiting
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
NCT06433609Advanced Breast Cancer
Beijing GoBroad Hospital
Phase 2
113
Beijing
2024-08-05
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsCamizestrant·Saruparib·Anastrozole·Exemestane
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Recruiting
Dalpiciclib in HR+/HER2- ABC
NCT06301438Advanced Breast Cancer
DrugDalpiciclib
RenJi Hospital
Observational
103
Shanghai
2024-05-03
By invitation
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
NCT07359404Advanced Breast Cancer
YING FAN
Phase 2
60
Beijing
2024-04-01
Not yet open
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
NCT06354114Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2
80
Harbin
2024-04
Recruiting
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
NCT06447623Advanced Breast Cancer, HR+/HER2- Breast Cancer
DrugApatinib
Fudan University
Phase 3
184
Shanghai
2024-02-01
Recruiting
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
NCT06217185HER2-positive Breast Cancer, Advanced Breast Cancer
DrugsPyrotinib·Trastuzumab·Capecitabine
Hebei Medical University Fourth Hospital
Phase 4
100
Shijiazhuang
2024-01-02
Recruiting
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
NCT06176534Advanced Breast Cancer, Treatment, HR Low/HER2 Negative
Henan Cancer Hospital
Phase 2
240
Zhengzhou
2024-01-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
NCT05949541Breast Cancer, Advanced Breast Cancer
DrugsDalpiciclib·Everolimus
Fudan University
Phase 2
265
Shanghai
2023-07-26
Recruiting
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
NCT05876065Advanced Breast Cancer
Wenjin Yin
Not applicable
86
Shanghai
2023-06-01
Recruiting
RC48-ADC in HER2-low Advanced Breast Cancer
NCT05831878Advanced Breast Cancer
DrugDisitamab Vedotin
RenJi Hospital
Not applicable
36
Shanghai
2023-05-04
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
DrugsARV-471·Fulvestrant
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Not yet open
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
NCT05431504Advanced Breast Cancer
DrugDalpiciclib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2022-06
Active, closed
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
NCT05257395Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3
397
Harbin
2022-03-14
Recruiting
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
NCT05142475Breast Cancer, Treatment Side Effects, Advanced Breast Cancer, Effects of Immunotherapy
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
50
Shanghai
2021-11-19
Active, closed
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
NCT05077449Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3
300
Beijing
2021-11-16
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
2019-12-10
Active, closed
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
NCT04539496Metastasis Solid Tumors, Advanced Breast Cancer
Sihuan Pharmaceutical Holdings Group Ltd.
Phase 1/2
402
Beijing
2018-05-22
Active, closed
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer
NCT06926088Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
500
Nanjing
2016-12
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies listing the condition Advanced Breast Cancer.

How many Advanced Breast Cancer trials are recruiting in China?

29 of the 46 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 9 have not yet opened recruitment, 7 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Breast Cancer), 46 studies
PhaseStudiesRecruitingShare
Phase 2231450%
Observational7515.2%
Phase 36213%
Phase 1326.5%
Not applicable224.3%
Phase 1/2214.3%
Phase 4224.3%
Phase EARLY_PHASE1112.2%

Most active sponsors

Lead sponsors with the most studies (Advanced Breast Cancer)
Lead sponsorStudiesRecruiting
Fudan University43
Wenjin Yin44
Henan Cancer Hospital32
Cancer Institute and Hospital, Chinese Academy of Medical Sciences21
RenJi Hospital22
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University21
The First Affiliated Hospital with Nanjing Medical University21
Xuanzhu Biopharmaceutical Co., Ltd.20
Akeso11
AstraZeneca11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.